2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial
- 28 June 2012
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 380 (9840), 475-483
- https://doi.org/10.1016/s0140-6736(12)60691-6
Abstract
No abstract availableKeywords
Funding Information
- Boehringer Ingelheim
This publication has 29 references indexed in Scilit:
- Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered ApproachDiabetes Care, 2012
- National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participantsThe Lancet, 2011
- Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trialDiabetes, Obesity and Metabolism, 2010
- Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled studyDiabetes, Obesity and Metabolism, 2010
- Patient-reported tolerability issues with oral antidiabetic agents: Associations with adherence; treatment satisfaction and health-related quality of lifeDiabetes Research and Clinical Practice, 2010
- Statement by an American Association of Clinical Endocrinologists/ American College of Endocrinology Consensus Panel on Type 2 Diabetes Mellitus: An Algorithm for Glycemic ControlEndocrine Practice, 2009
- Is the Combination of Sulfonylureas and Metformin Associated With an Increased Risk of Cardiovascular Disease or All-Cause Mortality?Diabetes Care, 2008
- Glycaemic control and adverse events in patients with type 2 diabetes treated with metformin + sulphonylurea: a meta‐analysisDiabetes, Obesity and Metabolism, 2008
- Defining and Reporting Hypoglycemia in DiabetesDiabetes Care, 2005
- Glycemic Control With Diet, Sulfonylurea, Metformin, or Insulin in Patients With Type 2 Diabetes MellitusProgressive Requirement for Multiple Therapies (UKPDS 49)Jama-Journal Of The American Medical Association, 1999